ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 913

Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis

Alan Rathbun1, Michelle Shardell 2, Joseph Gallo 3, Alice Ryan 1, Elizabeth Stuart 3, Megan Schuler 4, Michelle Yau 5 and Marc C. Hochberg 1, 1University of Maryland School of Medicine, Baltimore, MD, 2National Institute on Aging, Baltimore, MD, 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 4RAND Corporation, Boston, MA, 5Hebrew SeniorLife Institute for Aging Research, Boston, MA

Meeting: ACR/ARP Annual Meeting 2019

Keywords: analgesics and Chronic pain, depression, Osteoarthritis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S106: Osteoarthritis – Clinical I: Innovations (909–914)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Depression often accompanies knee osteoarthritis (OA), exacerbating the severity and persistence of pain, and may negatively affect clinical outcomes associated with analgesic treatment. This study evaluated whether depression moderates (Figure 1) the effectiveness of analgesics on knee pain severity in knee OA.

Methods: Eligible participants (n=1,477) were identified from the Osteoarthritis Initiative and were not using analgesics (acetaminophen, non-steroidal anti-inflammatory drugs, or opioids) at baseline (time t) and had radiographic disease (Kellgren-Lawrence [K-L] grade 2, 3, or 4) at the first annual follow-up visit (time t+1). Analgesic initiation and utilization was assessed at the first three annual follow-up visits (time t+1, time t+2, time t+3), and depression was evaluated concurrent to analgesic use with the Center for Epidemiological Studies Depression (CES-D) scale and corresponding screening threshold (CES-D score ≥ 16). Knee pain severity from the second to the fourth annual follow-up visit (time t+2, time t+3, time t+4) was measured with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale (rescaled range = 0-100). Time-invariant and time-varying confounders measured at time t and time t+1, time t+2, and time t+3 were age, sex, race, education, marital status, employment, health insurance, smoking, alcohol consumption, Charlson comorbidity index, and symptomatic knee OA status; and K-L grade, body mass index, physical performance, knee injuries, knee injections, and WOMAC pain score, respectively. Structural nested mean models appropriate for evaluating time-varying effect moderation were implemented using an inverse-probability-of-treatment-weighting regression-with-residuals approach.

Results: In non-depressed participants, analgesic treatment at years one, two, and three had minimal effect (Table 1) on knee pain severity at years two, three, and four, respectively, and time-specific associations ranged from -1.16 (95% CI: -3.48, 1.16) to 0.76 (95% CI: -1.67, 3.18). Moreover, persistent use of analgesics did not increase the magnitude of the treatment effect in non-depressed participants. By contrast, time-specific treatment effects in depressed participants increased during follow-up from -0.42 (95% CI: -7.56, 6.72) to -15.51 (95% CI: -26.13, -4.89), and the association between year three analgesic use and year four knee pain severity was statistically significant. The magnitude of the associations increased with persistent analgesic use in depressed participants, primarily due to significant effect moderation concerning year three analgesic use, where the subsequent difference in treatment effect between depressed and non-depressed participants was -16.27 (95% CI: -27.12, -5.42).

Conclusion: Findings indicate a statistically and clinically significant greater one-year treatment effect of analgesic use that lowered knee pain severity in persons with knee OA and depression. Thus, OA patients with depression may derive more benefit from analgesic treatment for chronic knee pain than non-depressed patients, perhaps because their pain is undertreated.


Figure_1

Figure 1


Table_1

Table 1


Disclosure: A. Rathbun, None; M. Shardell, None; J. Gallo, None; A. Ryan, None; E. Stuart, None; M. Schuler, RAND Corportation, 3; M. Yau, None; M. Hochberg, Bioiberica SA, 5, Bone Therapeutics, 5, BriOri Biotech, 4, Bristol Myers Squibb, 5, Eli Lilly, 5, Elsevier, 7, EMD Serono, 5, EMD Serono Research and Development Institute, Inc., 5, Galapagos, 5, Galapagos, IQVIA and Hoffman LaRoche, 9, IBSA Biotechniq SA, 5, Novartis Pharma AG, 5, Pfizer, 5, Pfizer Inc, 5, Plexxikon, 5, Regenosine, Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., and Zynerba, 5, Rheumcon, Inc, 3, Samumed LLC, 5, Theralogix LLC, 4, 5, TissueGene Inc, 5, UpToDateTM, 7.

To cite this abstract in AMA style:

Rathbun A, Shardell M, Gallo J, Ryan A, Stuart E, Schuler M, Yau M, Hochberg M. Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/depression-as-a-moderator-of-analgesic-effectiveness-in-knee-osteoarthritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-as-a-moderator-of-analgesic-effectiveness-in-knee-osteoarthritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology